Chemours Co (CC) FY2025 10-K Annual Report

Filed: Feb 24, 2026
Health Care
Chemicals & Allied ProductsSEC EDGAR

Chemours Co (CC) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 24, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.

Chemours Co FY2025 10-K Analysis

Business Overview

  • Core business: global provider of performance chemicals serving diverse industries via three segments—Thermal & Specialized Solutions, Titanium Technologies, Advanced Performance Materials
  • New strategy "Pathway to Thrive" launched in 2024 focusing on operational excellence, growth in data center cooling, next-gen refrigerants, and semiconductor fabrication
  • Strategic shift toward portfolio management emphasizing higher-margin, higher-growth applications and optimizing asset footprint
  • Approximately 2,400 customers served in ~110 countries via 28 production facilities across 8 countries
  • Titanium Technologies segment advancing "Transformation Plan" to become one of lowest-cost, high-quality TiO2 pigment producers

Management Discussion & Analysis

  • Revenue $5.758B, down 2% YoY; Thermal & Specialized Solutions up $236M (13%) to $2.1B, Titanium Technologies down $143M (6%) to $2.4B, Advanced Performance Materials down $63M (5%) to $1.3B
  • Profitability: Thermal & Specialized Solutions Adj. EBITDA margin 32% vs 31%, Titanium Technologies margin 6% vs 12%, Advanced Performance Materials margin 9% vs 12%
  • Best segment: Thermal & Specialized Solutions Adj. EBITDA $670M, up 17%; Worst segment: Titanium Technologies Adj. EBITDA $145M, down 52%
  • Cash flow & capital: $670M cash ($447M foreign), Revolving Credit Facility availability $955M, Corporate expenses down $75M to $181M, Supply chain financing accelerated $414M receivables collections with $6M discount
  • Outlook/risks: Tax Act impact under ongoing review, operational disruption risks (rail and shutdowns), Moody's Ba3 rating negative outlook, liquidity expected adequate through Feb 2027

Risk Factors

  • Litigation risk: $270 million settlement charge with State of New Jersey for environmental litigation in 2025
  • Geopolitical risk: Sale of Taiwan Titanium site for $360 million pending local regulatory and environmental approvals, mid-2026
  • Operational risk: Washington Works fluoropolymer plant outage caused $20-$25 million Q1 2026 earnings impact due to utility disruption and winter weather
  • Competitive risk: Titanium Technologies mine idled in Florida, shifting to third-party contractor to reduce costs and improve cash flow
  • Financial risk: $1.05 billion senior secured term loan maturity extended to October 2032 with adjusted SOFR +3.5% margin

Chemours Co FY2025 Key Financial Metrics
XBRL

Revenue

$5.8B

+0.4% YoY

Net Income

-$386M

-548.8% YoY

Gross Margin

15.5%

-438bp YoY

Net Margin

-6.6%

-813bp YoY

ROE

-154.4%

-16864bp YoY

Total Assets

$7.4B

-1.8% YoY

EPS (Diluted)

$-2.57

-550.9% YoY

Operating Cash Flow

$264M

+141.7% YoY

Source: XBRL data from Chemours Co FY2025 10-K filing on SEC EDGAR. All figures in USD.

Get deeper insights on Chemours Co

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.